CD274 and neoplasm: Based on these clinical trial data, pembrolizumab is approved by the FDA in advancedsquamous and nonsquamous NSCLC as first-line systemic therapy for patients withPD-L1 expression [22C3 immunohistochemical staining (IHC) with >50% TPS) or as asecond-line systemic therapy after progression on first-line chemotherapy, with atleast 1% PD-L1 expression on tumor cells.